age1
Venture capitalSan Francisco · Pre-Seed–Series A · 9 people tracked
Investment thesis
age1 backs contrarian founders developing therapeutics, tools, and technologies that target aging and age-related disease to extend healthy lifespan. The firm frames the shift from 'sickcare' to healthcare — preventing the onset of age-related disease rather than treating individual conditions — as a transformative moment in medicine. age1 invests at the earliest possible stage, often before any capital has been raised or even before a formal idea exists, and aims to build a pragmatic, rigorous, and optimistic longevity community. It prefers to lead rounds to secure founder-friendly terms and is capitalized to follow on in later rounds. It evolved from the Longevity Fund and a 2018 accelerator into a dedicated firm.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website
What they invest in
from 24 of 26 portfolio companiesBiotech ×24Healthtech ×12Deep Tech ×10Longevity ×8AI & Machine Learning ×7Medical Devices ×4Digital Health ×2
HQs:United States×15
Who they back
founder profiles across 14 portfolio companiesFounding team size:solo founder×72 founders×43 founders×24+ founders×1
Where their founders worked beforefrom 11 founders with career history
OpenAI ×2University of California, San Francisco ×2
Investments · 26 tracked
founders shown can be your intro pathBy year:2026 · 22025 · 12019 · 12015 · 15 dated
ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.
BiotechHealthtech
Co-investorsForesite CapitalLightstone VenturesvenBio Partners
Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.
BiotechDeep TechHealthtechCambridge, US
Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)
Co-investorsAtlas VentureAvoro Capital AdvisorsEcoR1 CapitalForesite Capital
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)
Co-investorsAliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)Pontifax AgTech+4 more
Autonomy Bio is a biotech company developing drugs targeting human aging to extend healthy lifespan.
BiotechLongevitySan Francisco, US
Co-investorsValhalla VenturesKleiner PerkinsSoftBank Group
Aerska develops RNA interference (RNAi) medicines designed for targeted delivery across the blood-brain barrier to treat, delay, and prevent central nervous system and neurological diseases.
BiotechDeep TechHealthtechMedical Devices
Stuart Milstein(Co-Founder)Jack O’MearaJack O'Meara(Cofounder)in
Co-investorsBlueYard CapitalEntrepreneur FirstIaso VenturesPsyMed VenturesUnruly CapitalAda Ventures
Aperture Therapeutics uses machine learning to mine genomic and clinical datasets for naturally occurring protective gene variants, then designs oligonucleotide therapeutics that mimic those variants to treat neurodegenerative diseases such as ALS and FTD and delay brain aging.
AI & Machine LearningBiotechLongevity
Martin Jacko(Founder & CEO)
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases.
AI & Machine LearningBiotechMedical DevicesAustin, US
Adam Freund(Founder & Chief Executive Officer)Remi-Martin Laberge(Founder and Chief Technology Officer)
BoardVineeta Agarwala(Director)in
Co-investorsAndreessen HorowitzStrawberry Creek VenturesAlumni VenturesGaingelsGV (Google Ventures)Indicator Ventures+3 more
Conception develops stem cell technology to create functional reproductive cells in the laboratory, enabling in-vitro gametogenesis as a solution for individuals facing biological and medical fertility barriers.
BiotechDeep TechHealthtech
Matt Krisiloff(CEO)inBianka Seres(President)
Co-investorsCompoundHOF CapitalMetaplanetSciFoundersVU Venture Partners
Originator of Otarmeni (lunsotogene parvec-cwha), an FDA-approved gene therapy for genetic hearing loss; acquired by Regeneron in 2023.
Cambridge, US
Co-investorsSamsara BioCapitalThird Rock Ventures
Deciduous Therapeutics develops small molecule and immunomodulatory therapies targeting senescent cells to treat age-related diseases including Type 1 diabetes, autoimmunity, and metabolic disorders.
BiotechDigital HealthLongevitySan Francisco, US
Robin Mansukhani(CEO and Co-Founder)inAnil Bhushan(Scientific Founder)in
BoardDylan Morris(Director)in
Co-investorsBold Capital PartnersCornucopian Capital ManagementCRV (Charles River Ventures)Owl CapitalquadraScope Venture FundAxial VC+1 more
Fauna Bio applies AI and computational analysis to its proprietary biobank of data from extreme mammals such as hibernating species to identify drug targets that are conserved across species including humans.
AI & Machine LearningBiotechDeep TechHealthtechEmeryville, US
Linda Goodman(Founder)inAshley(CEO)
Co-investorsFarvatn VentureGRIDS CapitalLifeforce CapitalMetaplanetVibe CapitalBeagle Ventures+3 more
General Control is developing programmable, multiplexed epigenetic editing therapies designed to control the expression of several genes at once.
BiotechDeep TechLongevity
Lada Nuzhna(CEO & Founder)
Co-investorsAngel Collective Opportunity FundGoAhead VenturesMoth FundStreamlined Ventures
General Proximity develops proximity-based technologies for drug discovery and development.
AI & Machine LearningBiotechDeep TechHealthtechSan Francisco, US
Armand Cognetta(Founder)in
Co-investorsY CombinatorFelicis VenturesModi Ventures
Gordian Biotechnology develops therapies aimed at treating age-related diseases to extend healthy lifespan.
AI & Machine LearningBiotechHealthtechLongevity
Co-investorsFifty YearsMetaplanetPrime Movers LabStreamlined VenturesW ventures10x Founders
The Longevity Fund is a venture capital firm founded in 2011 to back founder-led biotech companies developing drugs for longevity and age-related diseases.
BiotechLongevity
Laura Deming(Founder)Alex Colville(General Partner)
Co-investors1517
Loyal develops therapeutics to help dogs live longer and healthier lives, focusing on canine aging research and longevity interventions for companion dogs.
BiotechHealthtechLongevity
Celine Halioua(Founder & CEO)in
Co-investorsCollaborative FundFirst Round CapitalFlucas VenturesKhosla VenturesMetaplanetShrug Capital+4 more
Therapies for gastrointestinal and liver disease (NASDAQ: MTCR).
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Co-investorsEcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo CapitalARCH Venture Partners+2 more
BiotechCambridge, US
Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)
BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)
Co-investorsBrace PharmaSanofi VenturesAtlas VenturePolaris PartnersSR One Capital Management
NewLimit develops epigenetic reprogramming medicines to extend healthspan and treat age-related diseases at the intersection of computer science and biotechnology.
AI & Machine LearningBiotechLongevitySouth San Francisco, US
Brian Armstrong(Co-founder, Board of Directors)inBlake Byers(Director)inJacob Kimmel(Director)inMichael Polansky(Executive Officer)
BoardZavain Dar(Director)in
Co-investorsS32Valor Equity Partners8VCAbstract VenturesBeyond CapitalDraper Associates+6 more
Reservoir Neuroscience is developing therapeutics aimed at repairing the blood-brain barrier.
BiotechHealthtechSan Francisco, US
Aaron Friedman(Executive Officer)Vladimir Senatorov(Director)
BoardTracy Saxton(Director)James Summers(Director)Brian Slingerland(Director)
Co-investorsDolby Family Ventures
Science Corporation develops brain-computer interface and neural engineering technology to restore vision, cognition, and mobility to patients with debilitating conditions.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesAlameda, US
Max Hodak(Chief Executive Officer)
Co-investorsArtis VenturesAvalanche VCBeyond CapitalConversion CapitalDuke Capital PartnersFifty Years+8 more
Skeletalis is developing OASIS, a targeted small-molecule platform for musculoskeletal and bone health that concentrates therapy at sites of active bone loss while preserving the body's natural bone remodeling.
BiotechDeep TechHealthtech
Unity Biotechnology was a biotechnology company that is no longer operating.
BiotechBrisbane, US
Co-investorsARCH Venture PartnersCycad Group LLCEcoR1 CapitalKhosla VenturesVenrock
Until develops reversible cryopreservation systems for human donor organs, translating cryobiology into engineered workflows across perfusion, cryoprotectants, cooling, rewarming, and organ-health assessment.
BiotechDeep TechMedical Devices
Co-investorsLux Capital
Exits · 5
IPOs and acquisitions across the tracked portfolioAlx OncologyNASDAQ: ALXOIntellia TherapeuticsNASDAQ: NTLAPrecision BioSciencesNASDAQ: DTILDecibel Therapeuticsacq. by RegeneronDecibeltxacq. by Regeneron
Portfolio news
latest coverage across their companies
Alx Oncology · investing.com · Aug 18, 2026
Autonomy · defensedaily.com · Aug 18, 2026
Precision BioSciences · tradingkey.com · Aug 6, 2026
Reservoirneuro · intelligence360.news · Jul 30, 2026
Longevity Fund · altss.com · Jun 3, 2026
General Proximity · pulse2.com · May 5, 2026
Loyal · petage.com · Feb 12, 2026
Frequently asked questions
- How many investments has age1 made?
- age1 has 24 tracked investments, 3 of which have exited via acquisition or IPO, including 2 dated in the last 24 months.
- What stage does age1 invest at?
- age1 invests at the Pre-Seed, Seed, Series A stages.
- What is age1's typical check size?
- age1 typically writes checks of $500K – $4M.
- What sectors does age1 focus on?
- age1 focuses on Biotech, Healthtech, Longevity.
- Where is age1 located?
- age1 is headquartered in San Francisco, US.
- Does age1 lead rounds?
- Yes, age1 leads investment rounds.
- Who does age1 co-invest with?
- age1 most often shares deals with Metaplanet, EcoR1 Capital, Khosla Ventures, among 80 tracked co-investors.
Media · Podcasts & interviews
featuring the teamRoundtable with Alex Colville of AGE1: Revolutionizing Global Healthcare
Longevity Biotechnology Association · Alex Colville
Dr. Alex Colville, Ph.D., Co-Founder & General Partner - age1 - Longevity Biotech Venture Investing
Progress, Potential, and Possibilities · Alex Colville
Dr. Alex Colville, Ph.D. - Co-Founder and General Partner - age1
Progress, Potential, and Possibilities · Alex Colville
Age1’s Alex Colville: “Inventing the anti-ageing pill” - The Times Tech Podcast | Acast
Alex Colville · shows.acast.com
Images
Co-investors · 3
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Abstract is a San Francisco-based venture capital firm managing $1.8 billion in assets, investing in seed and early-stage companies across all sectors.
Refactor is a seed-stage venture firm run as a solo capitalist by Zal, backing founders building hard tech companies that address real-world problems.
Firms observed investing alongside age1, from public investor directories. Shared companies are the overlap with age1's recorded portfolio.
Similar investors
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
AlleyCorp is an early-stage investor and incubator based in New York that builds and backs companies across enterprise, consumer, healthcare, and deep tech sectors.
Illumina Ventures is a venture investor focused on genomics and precision health, aiming to advance innovation and impact in human health.
InnoCom Bio Equities manages life science special purpose vehicles, offering investors a diversified portfolio of innovative life sciences technologies and providing seed capital to innovators and founders.